{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:24:42Z","timestamp":1792783482769,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"2023 Annual Corps Guiding Science and Technology Plan Project of Shihezi University","award":["Project No. 2023ZD021"],"award-info":[{"award-number":["Project No. 2023ZD021"]}],"id":[{"id":"https:\/\/ror.org\/04x0kvm78","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Grant No. 81860374"],"award-info":[{"award-number":["Grant No. 81860374"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The 2021 University-Level Scientific Research Project Independently Supported by Shihezi University","award":["Grant No. ZZZC202186"],"award-info":[{"award-number":["Grant No. ZZZC202186"]}],"id":[{"id":"https:\/\/ror.org\/04x0kvm78","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04973-7","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T04:54:34Z","timestamp":1777092874000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acute promyelocytic leukemia with a unique genetic signature: a case report and management"],"prefix":"10.1007","volume":"17","author":[{"given":"Peixin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"4973_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040958","author":"MC Geoffroy","year":"2020","unstructured":"Geoffroy MC, De Th\u00e9 H. Classic and variants APLs, as viewed from a therapy response. Cancers. 2020. https:\/\/doi.org\/10.3390\/cancers12040958.","journal-title":"Cancers"},{"issue":"13","key":"4973_CR2","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1084\/jem.20131629","volume":"210","author":"GA Dos Santos","year":"2013","unstructured":"Dos Santos GA, Kats L, Pandolfi PP. Synergy against PML-RAR\u03b1: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med. 2013;210(13):2793\u2013802. https:\/\/doi.org\/10.1084\/jem.20131629.","journal-title":"J Exp Med"},{"issue":"11","key":"4973_CR3","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nrc2957","volume":"10","author":"H De Th\u00e9","year":"2010","unstructured":"De Th\u00e9 H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer. 2010;10(11):775\u201383. https:\/\/doi.org\/10.1038\/nrc2957.","journal-title":"Nat Rev Cancer"},{"key":"4973_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101536","author":"NI Nogueira","year":"2019","unstructured":"Nogueira NI, Catalano G, Banello C, et al. Acute promyelocytic leukemia: update on the mechanisms of leukemogenesis, resistance and on innovative treatment strategies. Cancers. 2019. https:\/\/doi.org\/10.3390\/cancers11101536.","journal-title":"Cancers"},{"issue":"4","key":"4973_CR5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood.V41.4.489.489","volume":"41","author":"J Bernard","year":"1973","unstructured":"Bernard J, Weil M, Biron M, et al. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood. 1973;41(4):489\u201396. https:\/\/doi.org\/10.1182\/blood.V41.4.489.489.","journal-title":"Blood"},{"issue":"6","key":"4973_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00514-3","volume":"11","author":"M Yilmaz","year":"2021","unstructured":"Yilmaz M, Kantarjian H, Ravandi F. Acute promyelocytic leukemia current treatment algorithms. Blood Cancer J. 2021;11(6):123. https:\/\/doi.org\/10.1038\/s41408-021-00514-3.","journal-title":"Blood Cancer J"},{"issue":"9","key":"4973_CR7","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1182\/blood.V89.9.3345","volume":"89","author":"GQ Chen","year":"1997","unstructured":"Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 1997;89(9):3345\u201353. https:\/\/doi.org\/10.1182\/blood.V89.9.3345.","journal-title":"Blood"},{"issue":"2","key":"4973_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1300874","volume":"369","author":"F Lo-Coco","year":"2013","unstructured":"Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1300874.","journal-title":"N Engl J Med"},{"issue":"1","key":"4973_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jamaoncol.2021.5816","volume":"8","author":"MA Kutny","year":"2022","unstructured":"Kutny MA, Alonzo TA, Abla O, et al. Assessment of arsenic trioxide and all-trans retinoic acid for the treatment of pediatric acute promyelocytic leukemia: a report from the children\u2019s oncology group AAML1331 trial. JAMA Oncol. 2022;8(1):79\u201387. https:\/\/doi.org\/10.1001\/jamaoncol.2021.5816.","journal-title":"JAMA Oncol"},{"issue":"1","key":"4973_CR10","first-page":"96","volume":"111","author":"B Yan","year":"2026","unstructured":"Yan B, Guryanova OA. Metallothionein 1: the Achilles heel of Dnmt3a;Npm1-mutant acute myeloid leukemia. Haematologica. 2026;111(1):96\u20137.","journal-title":"Haematologica"},{"issue":"2","key":"4973_CR11","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1158\/0008-5472.CAN-20-3033","volume":"81","author":"K Venugopal","year":"2021","unstructured":"Venugopal K, Feng Y, Shabashvili D, Guryanova OA. Alterations to DNMT3A in hematologic malignancies. Cancer Res. 2021;81(2):254\u201363.","journal-title":"Cancer Res"},{"key":"4973_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091311","author":"GL Picharski","year":"2019","unstructured":"Picharski GL, Andrade DP, Fabro A, Lenzi L, Tonin FS, Ribeiro RC, et al. The impact of Flt3 gene mutations in acute promyelocytic leukemia: a meta-analysis. Cancers. 2019. https:\/\/doi.org\/10.3390\/cancers11091311.","journal-title":"Cancers"},{"issue":"6","key":"4973_CR13","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/s41372-020-00873-0","volume":"33","author":"V Alfonso","year":"2019","unstructured":"Alfonso V, Iaccarino L, Ottone T, et al. Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia. Leukemia. 2019;33(6):1527\u201330. https:\/\/doi.org\/10.1038\/s41372-020-00873-0.","journal-title":"Leukemia"},{"issue":"1","key":"4973_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1172\/jci.82512","volume":"126","author":"CB Cole","year":"2016","unstructured":"Cole CB, Verdoni AM, Ketkar S, et al. PML-RARA requires DNA methyltransferase 3A to initiate acute promyelocytic leukemia. J Clin Invest. 2016;126(1):85\u201398. https:\/\/doi.org\/10.1172\/jci.82512.","journal-title":"J Clin Invest"},{"issue":"5","key":"4973_CR15","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.3324\/haematol.2018.205578","volume":"104","author":"L Wen","year":"2019","unstructured":"Wen L, Xu Y, Yao L, et al. Clinical and molecular features of acute promyelocytic leukemia with variant retinoid acid receptor fusions. Haematologica. 2019;104(5):e195\u20139. https:\/\/doi.org\/10.3324\/haematol.2018.205578.","journal-title":"Haematologica"},{"issue":"11","key":"4973_CR16","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1182\/bloodadvances.2021006682","volume":"6","author":"ZD Epstein-Peterson","year":"2022","unstructured":"Epstein-Peterson ZD, Derkach A, Geyer S, et al. Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia. Blood Adv. 2022;6(11):3433\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2021006682.","journal-title":"Blood Adv"},{"issue":"6","key":"4973_CR17","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ebiom.2015.09.014","volume":"2","author":"Y Shen","year":"2015","unstructured":"Shen Y, Fu YK, Zhu YM, et al. Mutations of epigenetic modifier genes as a poor prognostic factor in acute promyelocytic leukemia under treatment with all-trans retinoic acid and arsenic trioxide. EBioMedicine. 2015;2(6):563\u201371. https:\/\/doi.org\/10.1016\/j.ebiom.2015.09.014.","journal-title":"EBioMedicine"},{"issue":"6","key":"4973_CR18","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1038\/s41372-020-00873-0","volume":"33","author":"J Zhao","year":"2019","unstructured":"Zhao J, Liang JW, Xue HL, et al. The genetics and clinical characteristics of children morphologically diagnosed as acute promyelocytic leukemia. Leukemia. 2019;33(6):1387\u201399. https:\/\/doi.org\/10.1038\/s41372-020-00873-0.","journal-title":"Leukemia"},{"issue":"3","key":"4973_CR19","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1182\/bloodadvances.2021000595","volume":"6","author":"G O\u00f1ate","year":"2022","unstructured":"O\u00f1ate G, Bataller A, Garrido A, et al. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Adv. 2022;6(3):882\u201390. https:\/\/doi.org\/10.1182\/bloodadvances.2021000595.","journal-title":"Blood Adv"},{"issue":"1","key":"4973_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40364-021-00033-1","volume":"9","author":"X Zhang","year":"2021","unstructured":"Zhang X, Sun J, Yu W, et al. Current views on the genetic landscape and management of variant acute promyelocytic leukemia. Biomarker Res. 2021;9(1):33. https:\/\/doi.org\/10.1186\/s40364-021-00033-1.","journal-title":"Biomarker Res"},{"key":"4973_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.828852","volume":"12","author":"B Song","year":"2022","unstructured":"Song B, Wang X, Kong X, et al. Clinical response to Venetoclax and Decitabine in acute promyelocytic leukemia with a novel RARA-THRAP3 fusion: A case report. Front Oncol. 2022;12:828852. https:\/\/doi.org\/10.3389\/fonc.2022.828852.","journal-title":"Front Oncol"},{"issue":"5","key":"4973_CR22","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1007\/s00277-025-06361-7","volume":"104","author":"O Morath","year":"2025","unstructured":"Morath O, Rinke J, Walter A, Crodel C, Meggendorfer M, Baer C, et al. Molecular predictors of venous and arterial thrombotic events in patients with myelofibrosis. Ann Hematol. 2025;104(5):2755\u201363.","journal-title":"Ann Hematol"},{"key":"4973_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040934","author":"A Segura-Diaz","year":"2020","unstructured":"Segura-Diaz A, Stuckey R, Florido Y, Gonzalez-Martin JM, Lopez-Rodriguez JF, Sanchez-Sosa S, et al. Thrombotic risk detection in patients with Polycythemia Vera: the predictive role of DNMT3A\/TET2\/ASXL1 mutations. Cancers. 2020. https:\/\/doi.org\/10.3390\/cancers12040934.","journal-title":"Cancers"},{"issue":"23","key":"4973_CR24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI197100","volume":"135","author":"B Yan","year":"2025","unstructured":"Yan B, Yuan Q, Buttigieg MM, Kaur P, McKee AR, Shabashvili DE, et al. Clonal hematopoiesis driven by Dnmt3a mutations promotes metabolic disease development in mice. J Clin Invest. 2025;135(23):e197100.","journal-title":"J Clin Invest"},{"key":"4973_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113451","volume":"220","author":"C Liang","year":"2021","unstructured":"Liang C, Qiao G, Liu Y, et al. Overview of all-trans-retinoic acid (ATRA) and its analogues: structures, activities, and mechanisms in acute promyelocytic leukaemia. Eur J Med Chem. 2021;220:113451. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113451.","journal-title":"Eur J Med Chem"},{"key":"4973_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20143522","author":"MA Moosavi","year":"2019","unstructured":"Moosavi MA, Djavaheri-Mergny M. Autophagy: new insights into mechanisms of action and resistance of treatment in acute promyelocytic leukemia. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20143522.","journal-title":"Int J Mol Sci"},{"key":"4973_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1404092","volume":"15","author":"Y Chen","year":"2024","unstructured":"Chen Y, Tong X, Lu R, et al. All-trans retinoic acid in hematologic disorders: not just acute promyelocytic leukemia. Front Pharmacol. 2024;15:1404092. https:\/\/doi.org\/10.3389\/fphar.2024.1404092.","journal-title":"Front Pharmacol"},{"issue":"9","key":"4973_CR28","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1080\/17512433.2021.1937782","volume":"14","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, Guo M, Hostetter TH, et al. Effect of renal impairment on arsenic accumulation, methylation capacity, and safety in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide. Expert Rev Clin Pharmacol. 2021;14(9):1173\u201382. https:\/\/doi.org\/10.1080\/17512433.2021.1937782.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"19","key":"4973_CR29","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1056\/NEJMc1401775","volume":"370","author":"HH Zhu","year":"2014","unstructured":"Zhu HH, Qin YZ, Huang XJ. Resistance to arsenic therapy in acute promyelocytic leukemia. N Engl J Med. 2014;370(19):1864\u20136. https:\/\/doi.org\/10.1056\/NEJMc1401775.","journal-title":"N Engl J Med"},{"key":"4973_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.871590","volume":"12","author":"L Guarnera","year":"2022","unstructured":"Guarnera L, Ottone T, Fabiani E, et al. Atypical rearrangements in APL-like acute myeloid leukemias: molecular characterization and prognosis. Front Oncol. 2022;12:871590. https:\/\/doi.org\/10.3389\/fonc.2022.871590.","journal-title":"Front Oncol"},{"issue":"10","key":"4973_CR31","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1007\/s12095-021-00555-5","volume":"23","author":"X Chen","year":"2021","unstructured":"Chen X, Fan S, Zhao Y, et al. Gene mutations in acute promyelocytic leukemia early death in patients treated with arsenic trioxide alone. Clin Transl Oncol. 2021;23(10):2171\u201380. https:\/\/doi.org\/10.1007\/s12095-021-00555-5.","journal-title":"Clin Transl Oncol"},{"key":"4973_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051264","author":"M Sobas","year":"2020","unstructured":"Sobas M, Talarn-Forcadell MC, Mart\u00ednez-Cuadr\u00f3n D, et al. PLZF-RAR(\u03b1), NPM1-RAR(\u03b1), and other acute promyelocytic leukemia variants: the PETHEMA registry experience and systematic literature review. Cancers. 2020. https:\/\/doi.org\/10.3390\/cancers12051264.","journal-title":"Cancers"},{"issue":"2","key":"4973_CR33","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1111\/bjh.17477","volume":"195","author":"M Liu","year":"2021","unstructured":"Liu M, Zhao X, Pan W, et al. A novel HNRNPC-RARA fusion in acute promyelocytic leukaemia lacking PML-RARA rearrangement, sensitive to venetoclax-based therapy. Br J Haematol. 2021;195(2):e123\u20138. https:\/\/doi.org\/10.1111\/bjh.17477.","journal-title":"Br J Haematol"},{"key":"4973_CR34","doi-asserted-by":"publisher","first-page":"1028651","DOI":"10.3389\/fonc.2022.1028651","volume":"12","author":"W Ding","year":"2022","unstructured":"Ding W, Weng G, Wang Z, et al. Case report: identification of a novel HNRNPC::RARG fusion in acute promyelocytic leukemia lacking RARA rearrangement. Front Oncol. 2022;12:1028651. https:\/\/doi.org\/10.3389\/fonc.2022.1028651.","journal-title":"Front Oncol"},{"key":"4973_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16184771","author":"D Kegyes","year":"2024","unstructured":"Kegyes D, Thiagarajan PS, Ghiaur G. MRD in acute leukemias: lessons learned from acute promyelocytic leukemia. Cancers. 2024. https:\/\/doi.org\/10.3390\/cancers16184771.","journal-title":"Cancers"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04973-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04973-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04973-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:01:39Z","timestamp":1790517699000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04973-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4973"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04973-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"23 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee (approval number 2203) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Ethics Committee of Science and Technology of The First Affiliated Hospital of Shihezi University (Approval No. KJ2024-262-01) on 12 June 2024.The patient has provided consent for anonymous publication of this case to contribute to medical advancement. Written informed consent was obtained from all individual participants or for minors, from their legal guardians prior to their inclusion in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and approved the final version of this manuscript and consent to its publication in Discover Oncology. The manuscript does not contain any individual person\u2019s identifiable data, images, or clinical details.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"865"}}